A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs GSK 958108 (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Acronyms PoM
- Sponsors GlaxoSmithKline
- 19 Oct 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2009 New trial record